Next generation sequencing and anti-cancer therapy
Journal of the Korean Medical Association
;
: 119-129, 2019.
Artigo
em Coreano
| WPRIM
| ID: wpr-766562
ABSTRACT
Over the last two decades, the systemic treatment of cancer has evolved from cytotoxic chemotherapy to targeted therapy and now immunotherapy. Next-generation sequencing (NGS) is entering clinical applications for cancer treatment through the help of more powerful computational analyses. The increasing number of targeted therapies approved by regulatory authorities (RAs) with or without biomarkers necessitates the screening of multiple biomarkers using NGS, which is now approved and reimbursed by Korean RAs for some types of malignancies. However, the clinical utility of NGS remains to be established as a prerequisite for its routine incorporation into clinical practice. Currently, the best scenario of NGS use in clinics is to enroll patients into clinical trials based on the detection of biomarkers, but this is only possible in the hospitals conducting the specific trial. The other scenario is the off-label use of a targeted drug, but this requires social consensus for future implementation. The clinical applications of NGS are expanding in terms of its platforms, from targeted sequencing to whole exome and RNA sequencing, and in terms of systemic therapy, from targeted therapy to immunotherapy. Research into tumor mutational burden and neoantigens is shedding new light on the clinical use of NGS in immunotherapy.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Biomarcadores
/
Programas de Rastreamento
/
Análise de Sequência de RNA
/
Consenso
/
Tratamento Farmacológico
/
Uso Off-Label
/
Exoma
/
Imunoterapia
Tipo de estudo:
Guia de Prática Clínica
/
Estudo de rastreamento
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of the Korean Medical Association
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS